W. Christopher Ehmann

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

Yaxian Kong, Liuluan Zhu, Todd D. Schell et al. · Clinical Cancer Research · 2016 · 293 citations

Life Sciences, Hematology, Immunology +17

Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

Eric J. Feldman, Joseph Brandwein, Richard M. Stone et al. · Journal of Clinical Oncology · 2005 · 249 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

Brad S. Kahl, Fangxin Hong, Michael E. Williams et al. · Journal of Clinical Oncology · 2014 · 194 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Liru Wang, Bei Jia, David F. Claxton et al. · OncoImmunology · 2018 · 176 citations · Full text

Medicine, Immunology, Oncology +17

PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation

Yaxian Kong, J Zhang, David F. Claxton et al. · Blood Cancer Journal · 2015 · 146 citations · Full text

Life Sciences, Hematology, Immunology +17